I've been a share holder in IMM for a while now. I'm just sick to death of having no news, website needs updating. When looking at other pharma companies they are up dated on clinical trials and financials. Come on BOD at IMM, finger out and do something
You would certainly hope so Punk. Otherwise you'd start to wonder what hope there is for commercial exploitation (=shareholder added value) of Lupozor, the CNRS arrangement or the compounds in earlier stages of development with the current BOD.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.